ACE和sIL-2R与甲氨蝶呤治疗结节病时的肺功能改善相关
ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy
Adriane D.M. Vorselaarse, Coline H.M. van Moorsel, Pieter Zanen, Henk J.T. Ruven, Anke M.E. Claessen, Heleen van Velzen-Blad, Jan C. Grutters
Introduction
In sarcoidosis, the search for disease activity markers that correlate with treatment response is ongoing. The aim of this study was to investigate the pattern of two proposed markers, serum angiotensin-converting enzyme (ACE) and soluble IL-2 receptor (sIL-2R) during methotrexate (MTX) therapy in sarcoidosis patients.
Materials and methods
We analysed 114 sarcoidosis patients who used MTX for six months, consisting of a subgroup of 76 patients with a pulmonary indication for treatment and a subgroup of 38 patients with an extra-pulmonary indication. ACE and sIL-2R serum levels were measured at baseline and after six months of treatment. Correlation coefficients (R) and odds ratios (ORs) were calculated to study the correlation and predictive effect of serum ACE and sIL-2R levels for pulmonary improvement.
Results
High baseline levels of ACE correlated significantly with lung function improvement after treatment (R = 0.45, p < 0.0001; stronger in the pulmonary subgroup R 0.57, p < 0.0001). ACE baseline levels >90 U/l predicted a 10% improvement in overall lung function (OR 3.55; CI 1.34–9.38), with the highest prediction level for 10% improvement in DLCO (OR 4.63; CI 1.23–17.4).
After six months of MTX, mean ACE decreased with 17.2 U/l (p < 0.0001) and sIL-2R with 1850 pg/ml (p < 0.0001). Decreases in both ACE and sIL-2R correlated with an increase in lung function. The strongest correlation was found with change in DLCO in the pulmonary subgroup (ACE R = 0.63, P < 0.0001; sIL-2R R = 0.56, P < 0.0001).
Conclusion
Baseline and serial serum ACE and sIL-2R levels correlate well with lung function improvement during MTX treatment. Serial measurements of these biomarkers are helpful in monitoring treatment effects in sarcoidosis patients.
respiratory medicine
February 2015Volume 109, Issue 2, Pages 279–285
DOI: http://dx.doi.org/10.1016/j.rmed.2014.11.009 |
copyright©金宝搏网站登录技巧 版权所有,未经许可不得复制、转载或镜像
京ICP证120392号 京公网安备110105007198 京ICP备10215607号-1 (京)网药械信息备字(2022)第00160号